Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal

13 Apr 2017

• By Jessica Merrill

Human brain illustrated with millions of small nerves - Conceptual 3d render

Related Content

Neuroscience Reaches A New Inflection Point, Big Biotechs Say

25 Jan 2017

Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016

28 Dec 2016

Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus

20 Dec 2016

Related Companies

Biogen, Inc.

Bristol Myers Squibb Company

iPierian, Inc.

Ionis Pharmaceuticals, Inc.

AbbVie Inc.

C2N Diagnostics, LLC

Additional Topics

Deals Research & Development Commercial Neurology BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.